Clinical records
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. US Food and Drug Administration. Medwatch 2004 safety alert. Zometa (zoledronic acid) injection. Available at: http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm#zometa (accessed Mar 2005).
- 2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117.
- 3. Ruggiero SJ, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534.
- 4. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21: 4253-4254.
- 5. Carter GD, Goss AN. Bisphosphonates and avascular necrosis of the jaws. Aust Prescriber 2004; 27: 32-33.
- 6. Pogrel MA. Bisphosphonates and bone necrosis. J Oral Maxillofac Surg 2004; 62: 391-392.
- 7. Schwartz HC. Osteonecrosis and bisphosphonates: correlation versus caution. J Oral Maxillofac Surg 2004; 62: 763-764.
- 8. Lugassy G, Shaham R, Nemets A, et al. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med 2004; 117: 440-441.
- 9. The Maxillofacial Center for Diagnostics and Research. The history of maxillofacial osteonecrosis. Available at: http://maxillofacialcenter.com/NICOhistory.html (accessed Feb 2005).
- 10. Novartis Pharmaceuticals Australia. Aredia product information. Sydney: Novartis, May 2004.
- 11. Greenberg MS. Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98: 259-260.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
We acknowledge the contributions of Dr John McEwen, (Principal Medical Adviser, Therapeutic Goods Administration) and Associate Professor Duncan Topliss (Chairperson, ADRAC) to the preparation of this report.
None identified.